

SenesTech Launches New York City Sales for ContraPest Rodent Control Solution

FLAGSTAFF, AZ, March 13th, 2017 – SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today it is beginning its city wide collaboration with the New York Department of Health (DOH) targeting rat infestations within the City. The project will include participation from multiple public agencies and will utilize ContraPest, SenesTech's innovative rat fertility control product.

The commencement of rodent infestation estimates will begin this spring with targeted ContraPest deployment immediately following. The exact study sites, agencies and financial terms were not disclosed.

"The City of New York has been the leader in innovation to address the overwhelming problems that rodent reproduction brings to large urban areas. With our EPA and New York State registrations for ContraPest, the DOH has initiated a number of progressive measures to address rat infestations and we are looking forward to being a part of this integrated team," Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech, said. "Faced with decreasing budgets and increasing rodent infestations, many agencies serving the public find themselves in a challenging situation and need more effective, sustainable solutions."

"We continue to hear the frustration of our public health officials with killing strategies that cannot provide sustainable results," according to Mayer. "When you are up against one of nature's most successful breeding machines (where two rats can give rise to 15,000 in a year) you can never get ahead by killing - as history has shown us". Unlike rodenticide, which targets individual rats and can inadvertently affect non-targeted species, "ContraPest targets whole populations that carry disease, damage property and disturb the public by getting to the root of the problem: reproduction," Mayer said.

About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company's first fertility control product, ContraPest[®], is marketed for use initially in controlling rat infestations. ContraPest's novel technology and approach targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

We believe our non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations. We believe ContraPest[®] will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticides. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700,
senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc, 928-779-4143

<https://senestech.investorroom.com/press-releases?item=35>